The biosynthesis of the cholesterol-lowering drug lovastatin isolated from Aspergillus terreus has been investigated extensively by Vederas and coworkers [10]. Incorporation experiments with multiple labeled acetate and 18 O-oxygen suggested that it is biosynthesized via the polyketide pathway. Based on feeding studies and co-occurrence of 4a,5-dihydromonacolin L (3), this compound was speculated as an intermediate. This was confirmed by the successful conversion of 3 into lovastatin, using a blocked mutant of A. terreus (Scheme 21.2) [11]. Because lovastatin does not have an electron-withdrawing group in the dienophile moiety, it was proposed that the requisite Diels-Alder reaction occurred at the hexaketide stage. However, all efforts to convert 13 C-labeled hexaketide precursor 1b into lovastatin were unsuccessful due to non-enzymatic cycloadditions affording a 1 : 1 mixture of undesired diastereomers 4b (endo) and 4c (exo) in aqueous media (half life of 1b: two days) (Scheme 21.2). This clearly showed significant rate acceleration for the cycloaddition of 1b in aqueous media [12].